AACR announces launch of new journal, Tumor Discovery The American Association for Malignancy Study announces the launch of its newest journal, Cancer Discovery, which will publish high-impact, peer-reviewed articles describing main advances in basic and clinical research. Its exclusive format will feature game-changing research, review articles, commentaries and perspectives, news, and Research Watch summaries of essential journal articles. Cancers Discovery is a fresh addition to the AACR’s robust publication system abnormal uterine bleeding . Cancer Discovery combines the experience and knowledge of founding Editors-in-Chief Lewis C.
10, in order to help patients locate clinical trials that they qualify,’ said Margaret Foti, Ph.D., M.D. , CEO of the American Association for Malignancy Research. ‘SU2C’s objective is to supply effective treatments to sufferers quickly, which partnership with EmergingMed helps realize that goal. Moreover, the AACR aims to educate the public in what clinical trials can provide, to be able to help individuals make educated decisions about their treatment options.’ The AACR is the single scientific partner to SU2C. It is in charge of grants administration and management, and provides ongoing scientific oversight in conjunction with the SU2C Scientific Advisory Committee, led by Nobel Laureate Phillip A. Sharp, Ph.D., institute professor at the David H. Koch Institute for Integrative Cancers Study at the Massachusetts Institute of Technology.